Literature DB >> 23873474

Cardiovascular magnetic resonance characteristics in children with hypertrophic cardiomyopathy.

Yan Chaowu1, Zhao Shihua, Ling Jian, Li Li, Fang Wei.   

Abstract

BACKGROUND: Cardiovascular magnetic resonance has provided important information on the diagnosis and risk stratification of hypertrophic cardiomyopathy (HCM) in adults; however, comparable data are absent for HCM in children. The study was performed to evaluate cardiovascular magnetic resonance characteristics in children with idiopathic HCM. METHODS AND
RESULTS: Cardiovascular magnetic resonance was performed in 71 consecutive children with idiopathic HCM (age, 12.8±4.1 years; 46 boys and 25 girls). The left ventricular (LV) parameters indexed by body surface area were calculated and compared with those in 71 healthy children (age, 13.1±3.3 years; 51 boys and 20 girls). Among those with HCM, concentric LV hypertrophy occurred in 9 patients (12.7%): in 2 children, it progressed into end-stage phase. The prevalence of late gadolinium enhancement (LGE) was 73%, and the extent of LGE was 10.4±8.3% of LV mass. Children with HCM with LGE had greater LV mass indexed (112.7±57.9 versus 70.3±37.4 g/m(2); P=0.025) but had no significant difference in maximal LV wall thickness indexed (19.4±6.3 versus 18.1±7.9 mm/m(2); P=0.513). In addition, the hazard ratio of adverse events for the extent of LGE was 1.1 (P=0.004). The follow-up (2.4±1.6 years) demonstrated that LGE was associated with adverse events in children with HCM (log-rank; P=0.029).
CONCLUSIONS: The prevalence and extent of LGE in children with HCM approximate to those in adults with HCM. Furthermore, children with HCM with LGE tend to have adverse events, and larger researches with longer follow-up are required.

Entities:  

Keywords:  cardiomyopathy, hypertrophic; cardiovascular magnetic resonance; children/childhood; death, sudden, cardiac; heart failure; late gadolinium enhancement

Mesh:

Substances:

Year:  2013        PMID: 23873474     DOI: 10.1161/CIRCHEARTFAILURE.113.000414

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  13 in total

Review 1.  Utility of late gadolinium enhancement in pediatric cardiac MRI.

Authors:  Maryam Etesami; Robert C Gilkeson; Prabhakar Rajiah
Journal:  Pediatr Radiol       Date:  2015-12-30

2.  Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic Cardiomyopathy.

Authors:  Anna Axelsson Raja; Hoshang Farhad; Anne Marie Valente; John-Paul Couce; John Lynn Jefferies; Henning Bundgaard; Kenneth Zahka; Harry Lever; Anne M Murphy; Euan Ashley; Sharlene M Day; Mark V Sherrid; Ling Shi; David A Bluemke; Charles E Canter; Steven D Colan; Carolyn Y Ho
Journal:  Circulation       Date:  2018-08-21       Impact factor: 29.690

3.  Hypertrophic cardiomyopathy in children.

Authors:  Arman Arghami; Joseph A Dearani; Sameh M Said; Patrick W O'Leary; Hartzell V Schaff
Journal:  Ann Cardiothorac Surg       Date:  2017-07

Review 4.  Society for Cardiovascular Magnetic Resonance/European Society of Cardiovascular Imaging/American Society of Echocardiography/Society for Pediatric Radiology/North American Society for Cardiovascular Imaging Guidelines for the Use of Cardiac Magnetic Resonance in Pediatric Congenital and Acquired Heart Disease: Endorsed by The American Heart Association.

Authors:  Mark A Fogel; Shaftkat Anwar; Craig Broberg; Lorna Browne; Taylor Chung; Tiffanie Johnson; Vivek Muthurangu; Michael Taylor; Emanuela Valsangiacomo-Buechel; Carolyn Wilhelm
Journal:  Circ Cardiovasc Imaging       Date:  2022-06-21       Impact factor: 8.589

Review 5.  Society for Cardiovascular Magnetic Resonance/European Society of Cardiovascular Imaging/American Society of Echocardiography/Society for Pediatric Radiology/North American Society for Cardiovascular Imaging Guidelines for the use of cardiovascular magnetic resonance in pediatric congenital and acquired heart disease : Endorsed by The American Heart Association.

Authors:  Mark A Fogel; Shaftkat Anwar; Craig Broberg; Lorna Browne; Taylor Chung; Tiffanie Johnson; Vivek Muthurangu; Michael Taylor; Emanuela Valsangiacomo-Buechel; Carolyn Wilhelm
Journal:  J Cardiovasc Magn Reson       Date:  2022-06-21       Impact factor: 6.903

6.  Comparison of cardiovascular magnetic resonance characteristics and clinical consequences in children and adolescents with isolated left ventricular non-compaction with and without late gadolinium enhancement.

Authors:  Huaibing Cheng; Minjie Lu; Cuihong Hou; Xuhua Chen; Li Li; Jing Wang; Gang Yin; Xiuyu Chen; Wei Xiangli; Chen Cui; Jianmin Chu; Shu Zhang; Sanjay K Prasad; Jielin Pu; Shihua Zhao
Journal:  J Cardiovasc Magn Reson       Date:  2015-05-30       Impact factor: 5.364

7.  Gender-related differences in the association between serum uric acid and left ventricular mass index in patients with obstructive hypertrophic cardiomyopathy.

Authors:  Changlin Zhang; Rong Liu; Jiansong Yuan; Jingang Cui; Fenghuan Hu; Weixian Yang; Yan Zhang; Chengzhi Yang; Shubin Qiao
Journal:  Biol Sex Differ       Date:  2016-04-05       Impact factor: 5.027

8.  Echocardiography as a Screening Test for Myocardial Scarring in Children with Hypertrophic Cardiomyopathy.

Authors:  Gregory Compton; Lynne Nield; Andreea Dragulescu; Lee Benson; Lars Grosse-Wortmann
Journal:  Int J Pediatr       Date:  2016-11-15

9.  A feasible method for non-invasive measurement of pulmonary vascular resistance in pulmonary arterial hypertension: Combined use of transthoracic Doppler-echocardiography and cardiac magnetic resonance. Non-invasive estimation of pulmonary vascular resistance.

Authors:  Chaowu Yan; Zhongying Xu; Jinglin Jin; Jianhua Lv; Qiong Liu; Zhenhui Zhu; Kunjing Pang; Yisheng Shi; Wei Fang; Yang Wang
Journal:  Int J Cardiol Heart Vasc       Date:  2015-08-01

10.  Predictive Values of N-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin I for Myocardial Fibrosis in Hypertrophic Obstructive Cardiomyopathy.

Authors:  Changlin Zhang; Rong Liu; Jiansong Yuan; Jingang Cui; Fenghuan Hu; Weixian Yang; Yan Zhang; Youzhou Chen; Shubin Qiao
Journal:  PLoS One       Date:  2016-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.